JP2007516227A5 - - Google Patents

Download PDF

Info

Publication number
JP2007516227A5
JP2007516227A5 JP2006533150A JP2006533150A JP2007516227A5 JP 2007516227 A5 JP2007516227 A5 JP 2007516227A5 JP 2006533150 A JP2006533150 A JP 2006533150A JP 2006533150 A JP2006533150 A JP 2006533150A JP 2007516227 A5 JP2007516227 A5 JP 2007516227A5
Authority
JP
Japan
Prior art keywords
compound
disease
formula
group
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2006533150A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007516227A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2004/015444 external-priority patent/WO2004110998A1/en
Publication of JP2007516227A publication Critical patent/JP2007516227A/ja
Publication of JP2007516227A5 publication Critical patent/JP2007516227A5/ja
Withdrawn legal-status Critical Current

Links

JP2006533150A 2003-05-16 2004-05-17 ピロール化合物およびその使用 Withdrawn JP2007516227A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US47142503P 2003-05-16 2003-05-16
US48047503P 2003-06-20 2003-06-20
US48028903P 2003-06-20 2003-06-20
US48817803P 2003-07-16 2003-07-16
US48817203P 2003-07-16 2003-07-16
US51661603P 2003-10-30 2003-10-30
US51665103P 2003-10-30 2003-10-30
US51661003P 2003-10-30 2003-10-30
PCT/US2004/015444 WO2004110998A1 (en) 2003-05-16 2004-05-17 Pyrrole compounds and uses thereof

Publications (2)

Publication Number Publication Date
JP2007516227A JP2007516227A (ja) 2007-06-21
JP2007516227A5 true JP2007516227A5 (https=) 2007-08-02

Family

ID=33479880

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2006533154A Pending JP2007500219A (ja) 2003-05-16 2004-05-17 複素環化合物およびその使用法
JP2006533150A Withdrawn JP2007516227A (ja) 2003-05-16 2004-05-17 ピロール化合物およびその使用

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2006533154A Pending JP2007500219A (ja) 2003-05-16 2004-05-17 複素環化合物およびその使用法

Country Status (6)

Country Link
US (3) US20040242673A1 (https=)
EP (2) EP1636183A1 (https=)
JP (2) JP2007500219A (https=)
AU (2) AU2004247023A1 (https=)
CA (2) CA2523858A1 (https=)
WO (4) WO2004110357A2 (https=)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0302094D0 (en) 2003-01-29 2003-02-26 Pharmagene Lab Ltd EP4 receptor antagonists
GB0324269D0 (en) * 2003-10-16 2003-11-19 Pharmagene Lab Ltd EP4 receptor antagonists
ES2311986T3 (es) * 2004-04-26 2009-02-16 Alcon, Inc. Estatinas para el tratamiento de la hipertension ocular y del glaucoma.
EP1671947A1 (en) * 2004-12-20 2006-06-21 Ratiopharm GmbH Process for preparing pyrrole derivatives and intermediates
TWI444187B (zh) 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
BRPI0610283A2 (pt) 2005-05-13 2010-10-19 Virochem Pharma Inc composto, uso do mesmo na preparação de um medicamento para o tratamento ou prevenção de uma infecção por vìrus de hepatite c, composição farmacêutica e combinação farmacêutica
KR20080064956A (ko) 2005-09-27 2008-07-10 미리어드 제네틱스, 인크. 치료학적 화합물로서의 피롤 유도체
WO2007056457A2 (en) 2005-11-09 2007-05-18 Combinatorx, Incorporated Methods, compositions, and kits for the treatment of medical conditions
US7592362B2 (en) 2006-01-19 2009-09-22 Pfizer Limited Substituted imidazoles
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
MX2008010187A (es) 2006-02-10 2008-10-31 Summit Corp Plc Tratamiento de distrofia muscular de duchenne.
US9187485B2 (en) 2007-02-02 2015-11-17 Baylor College Of Medicine Methods and compositions for the treatment of cancer and related hyperproliferative disorders
EP2120580B1 (en) * 2007-02-02 2017-12-27 Baylor College Of Medicine Compositions and methods for the treatment of metabolic disorders
US8048880B2 (en) 2007-05-03 2011-11-01 Anthera Pharmaceuticals, Inc. Treatment of cardiovascular disease and dyslipidemia using secretory phospholipase A2 (SPLA2) inhibitors and SPLA2 inhibitor combination therapies
JP2010535708A (ja) * 2007-08-03 2010-11-25 ビオマリン アイジーエー リミテッド デュシェンヌ型筋ジストロフィーの治療のための薬物併用
GB0715937D0 (en) * 2007-08-15 2007-09-26 Vastox Plc Method of treatment og duchenne muscular dystrophy
JP5567481B2 (ja) 2007-10-09 2014-08-06 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング グルコキナーゼアクチベーターとして有用なピリジン誘導体
US20110009463A1 (en) * 2007-10-17 2011-01-13 Yuri Karl Petersson Geranylgeranyl transferase inhibitors and methods of making and using the same
AR069126A1 (es) 2007-10-31 2009-12-30 Janssen Pharmaceutica Nv Diaminas en puente o fusionadas sustituidas con arilo como moduladores de leucotrieno a4 hidrolasa
KR20090070233A (ko) * 2007-12-27 2009-07-01 동아제약주식회사 피롤릴헵탄산 화합물의 합성 중간체 및 신규 중간체를이용한 제조방법
KR100856133B1 (ko) * 2008-01-11 2008-09-03 조동옥 아토르바스타틴의 개선된 제조방법
DE102008007400A1 (de) 2008-02-04 2009-08-06 Bayer Healthcare Ag Substituierte Furane und ihre Verwendung
SI2336125T1 (sl) 2008-04-11 2013-04-30 Janssen Pharmaceutica N.V. Tiazolopiridin-2-iloksi-fenil in tiazolopirazin-2-iloksi-fenil amini kot modulatorji levkotrien a4 hidrolaze
US9447049B2 (en) * 2010-03-01 2016-09-20 University Of Tennessee Research Foundation Compounds for treatment of cancer
US9029408B2 (en) 2008-06-16 2015-05-12 Gtx, Inc. Compounds for treatment of cancer
AU2009330686B2 (en) 2008-06-16 2014-07-03 The Ohio State University Research Foundation Compounds for the treatment of cancer
WO2010056413A2 (en) * 2008-11-14 2010-05-20 Parkinson's Institute COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED α-SYNUCLEIN FUNCTION
CN102459251B (zh) 2009-05-14 2015-05-20 詹森药业有限公司 作为白三烯a4水解酶的调节剂的具有两个稠合双环杂芳基部分的化合物
US11084811B2 (en) 2010-03-01 2021-08-10 Oncternal Therapeutics, Inc. Compounds for treatment of cancer
MX2012010115A (es) 2010-03-01 2013-02-26 Gtx Inc Compuestos para el tratamiento de cancer.
MX2012014273A (es) 2010-06-07 2013-03-22 Novomedix Llc Compuestos furanilo y su uso.
WO2011154677A1 (en) * 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
US20140057953A1 (en) * 2011-03-03 2014-02-27 Rolf Hartmann Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
US20120328526A1 (en) * 2011-06-27 2012-12-27 University Of Maryland, Baltimore Modulation of Nad+ Activity in Neuropathophysiological Conditions and Uses Thereof
JP6835472B2 (ja) 2013-03-05 2021-02-24 ユニバーシティ オブ テネシー リサーチ ファウンデーション 癌の処置のための組成物
WO2014169087A2 (en) * 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
CN107074839A (zh) * 2013-08-29 2017-08-18 贝勒医学院 用于治疗代谢和体重相关的病症的组合物和方法
WO2016029263A1 (en) * 2014-08-25 2016-03-03 Wang Bing Hui Mapk inhibitors
ES2977619T3 (es) 2017-05-11 2024-08-27 Remynd N V Compuestos para el tratamiento de la epilepsia, trastornos neurodegenerativos y otros trastornos del SNC
EP3634407A1 (en) * 2017-05-11 2020-04-15 Remynd N.V. Inhibitors of pde6delta for use in the prevention and/or treatment of epilepsy and/or neurodegenerative disorders
CN108101891B (zh) * 2017-12-06 2020-08-21 浙江科技学院 一种阿托伐他汀中间体的制备方法
BR112020022220A2 (pt) * 2018-06-01 2021-02-02 Autophagysciences Inc. novo composto e composição farmacêutica compreendendo o mesmo
US20220265646A1 (en) * 2019-07-08 2022-08-25 Itä-Suomen Yliopisto Piezo agonists for preventing or reverting abnormal amyloid deposition
WO2021041744A1 (en) * 2019-08-30 2021-03-04 University Of Tennessee Research Foundation Ryl benzoyl imidazole compounds for the treatment of lung cancer
WO2023028117A1 (en) * 2021-08-24 2023-03-02 Yeh, Teng-Kuang Methods of treating cdgsh iron sulfur domain 2 insufficiency-associated disorders
WO2023101556A1 (en) 2021-12-02 2023-06-08 Rijksuniversiteit Groningen Novel inhibitors of aspartate transcarbamoylase (atcase) and compositions, methods and uses related thereto.
JPWO2023145831A1 (https=) * 2022-01-28 2023-08-03
CN117510430B (zh) * 2024-01-08 2024-10-25 南昌大学 一种噁唑类化合物及其合成方法与应用

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2714082A (en) * 1955-07-26 New oxazoline derivatives
US3803316A (en) * 1969-10-30 1974-04-09 Ciba Geigy Corp Control of helminths with 4-(isothiocyanophenyl)-thiazoles
JPS5612114B2 (https=) * 1974-06-07 1981-03-18
US4137322A (en) * 1976-11-02 1979-01-30 Sankyo Company Limited ML-236B carboxylic acid derivatives and their use as antihyperlipemic agents
JPS53147073A (en) * 1977-05-24 1978-12-21 Sankyo Co Ltd Mevalonolactone derivatives
JPS5559180A (en) * 1978-10-30 1980-05-02 Sankyo Co Ltd 4-hydroxy-2-pyrone ring compound, its preparation, and remedy for hyperlipemia comprising it as active constituent
US4375475A (en) * 1979-08-17 1983-03-01 Merck & Co., Inc. Substituted pyranone inhibitors of cholesterol synthesis
ATE11770T1 (de) * 1981-12-14 1985-02-15 Sandoz-Erfindungen Verwaltungsgesellschaft M.B.H. N,n,disubstituierte alkenamide und phenylaldenamide, verfahren zu deren herstellung und deren verwendung als pharmazeutika.
DK161312C (da) * 1982-03-11 1991-12-09 Pfizer Analogifremgangsmaade til fremstilling af 2-aminoalkoxymethyl-4-phenyl-6-methyl-1,4-dihydropyridin-3,5-dicarboxylsyreestere eller syreadditionssalte deraf samt phthalimidoderivater til anvendelse som udgangsmateriale ved fremgangsmaaden
US4596821A (en) * 1984-05-01 1986-06-24 Merck & Co., Inc. Treatment of gray matter edema with 3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones
EP0160891A1 (en) 1984-05-01 1985-11-13 Merck & Co. Inc. Substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-Hydroxy-1H-Pyrrole-2,5-diones, their analogs and their salts
US4605663A (en) * 1984-05-01 1986-08-12 Merck & Co., Inc. Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones, for treatment of grey matter edema
US4604403A (en) * 1984-05-01 1986-08-05 Merck & Co., Inc. Use of substituted-3(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treating grey matter edema
US4605664A (en) * 1984-05-01 1986-08-12 Merck & Co., Inc. Use of substituted-3-(2,3-dihydro-1H-inden-5-yl)-4-hydroxy-1H-pyrrole-2,5-diones for treatment of grey matter edema
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
GB8608335D0 (en) * 1986-04-04 1986-05-08 Pfizer Ltd Pharmaceutically acceptable salts
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) * 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) * 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) * 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) * 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5260305A (en) * 1988-12-12 1993-11-09 E. R. Squibb & Sons, Inc. Combination of pravastatin and nicotinic acid or related acid and method for lowering serum cholesterol using such combination
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248793A (en) * 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) * 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) * 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5656644A (en) * 1994-07-20 1997-08-12 Smithkline Beecham Corporation Pyridyl imidazoles
CA2139442A1 (en) * 1992-07-03 1994-01-20 David Haigh Heterocyclic compounds as pharmaceutical
ES2133158T3 (es) * 1993-01-19 1999-09-01 Warner Lambert Co Formulacion ci-981 oral, estable y proceso de preparacion del mismo.
US5298627A (en) * 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
TW334423B (en) 1993-10-22 1998-06-21 Hoffmann La Roche Tricyclic 1-aminoethylpyrrole-derivatives
KR100389518B1 (ko) * 1995-07-17 2003-11-15 워너-램버트 캄파니 엘엘씨 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴)
EP0859761A4 (en) 1995-09-15 2000-01-26 Merck & Co Inc 4-AZASTEROIDS FOR TREATING HYPERANDROGEN STATES
GB9600464D0 (en) * 1996-01-09 1996-03-13 Smithkline Beecham Plc Novel method
CZ298812B6 (cs) * 1996-07-01 2008-02-13 Dr. Reddy's Laboratories Limited Azolidindionové deriváty, způsob jejich přípravy, farmaceutické kompozice s jejich obsahem a jejich použití v léčbě diabetu a příbuzných nemocí
GT199800127A (es) * 1997-08-29 2000-02-01 Combinaciones terapeuticas.
CA2304505A1 (en) * 1997-09-24 1999-04-01 Nova Molecular, Inc. Methods for increasing apoe levels for the treatment of neurodegenerative disease
CN1280574A (zh) * 1997-10-27 2001-01-17 雷迪研究基金会 新的杂环化合物及其在医药中的应用、它们的制备方法和含有它们的药物组合物
AU749505B2 (en) * 1997-10-27 2002-06-27 Dr. Reddy's Laboratories Limited Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
CA2349832A1 (en) * 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
CN1230421C (zh) 1999-02-10 2005-12-07 三菱制药株式会社 酰胺化合物及其药物用途
JP4496586B2 (ja) * 2000-01-24 2010-07-07 日産化学工業株式会社 キノリルアクリロニトリルの製造法及びその中間体
WO2002057229A1 (en) * 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
US6987123B2 (en) * 2001-07-26 2006-01-17 Cadila Healthcare Limited Heterocyclic compounds, their preparation, pharmaceutical compositions containing them and their use in medicine
JP2005532982A (ja) 2001-09-24 2005-11-04 バイエル・フアーマシユーチカルズ・コーポレーシヨン 肥満の処置のためのピロール誘導体の製造及び使用
CA2464314A1 (en) * 2001-11-22 2003-05-30 Ciba Specialty Chemicals Holding Inc. Pyrrole synthesis
WO2003055479A1 (en) 2001-12-21 2003-07-10 Consejo Superior De Investigaciones Cientificas Compounds and their therapeutic use related to the phosphorylating activity of the enzyme gsk-3
EP1466902A4 (en) 2001-12-28 2005-11-09 Takeda Pharmaceutical ANTAGONISTS OF THE ANDROGEN RECEPTOR
AU2003203143B2 (en) 2002-02-01 2009-05-14 High Point Pharmaceuticals, Llc Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
HUP0201083A2 (hu) 2002-03-28 2004-06-28 Richter Gedeon Vegyészeti Gyár Rt. Új atorvastatinsók és az azokat tartalmazó gyógyszerkészítmények
US20030186221A1 (en) * 2002-04-02 2003-10-02 Lockhart David J. Phage display affinity filter and forward screen
AU2003234089A1 (en) 2002-04-12 2003-10-27 Henry Ford Health System Treatment of neural injury and neurodegenerative disease with statins
AU2004266232B2 (en) * 2003-08-15 2008-07-03 Merck Sharp & Dohme Corp. Mitotic kinesin inhibitors

Similar Documents

Publication Publication Date Title
JP2007516227A5 (https=)
CN101600438B (zh) 疼痛疾病治疗剂
US20250281463A1 (en) Dosing regimen for a selective s1p1 receptor agonist
JP2022502500A5 (https=)
JP2013545730A5 (https=)
HUE031253T2 (en) Tenofovir alafenamide hemifumarate
EP3831371A1 (en) Dosage regimen of an s1p receptor modulator
EP3908570B1 (en) Ketamine pamoate and use thereof
JP6708646B2 (ja) 神経変性障害
CA2525771A1 (en) Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
WO2012012347A3 (en) Methods of intravenous administration of glyburide and other drugs
WO2004103359A1 (en) Pharmaceutical combination comprising modafinil and another drug
MX2007008845A (es) Metodos para control del intervalo qt.
JP2020535139A (ja) シポニモドの投与レジメン
JP2020527172A5 (https=)
JP2023526517A (ja) 運動失調症を治療するためのアセチルロイシンと４－アミノピリジン又はアセタゾラミドとの組合せ
AU2023204098A1 (en) Dosage regimen of an S1P receptor modulator
CN108864015A (zh) 一种具有治疗神经退行性疾病功效的化合物及药物组合物
US20240277662A1 (en) Administration of a Compound to Individuals with Hepatic Impairment
Rittenhouse et al. Novel Treatments for Multiple Sclerosis
CN1244324C (zh) 精氨酸对糖尿病皮肤组织“隐性损害”的改善作用
US20050272805A1 (en) Treatment of gastrointestinal disorders with duloxetine
AU2015101631B4 (en) Dosage regimen of an S1P receptor modulator
WO2025019604A2 (en) Proteolysis targeting chimeras for treating neurodegeneration
Kim et al. Anesthetic experience of frontotemporal dementia patient with severe autonomic dysfunction: a case report